Clinical trial
Tuberculosis Treatment Shortening Trial
NCT00130247 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00130247 |
|---|---|
| Title | Tuberculosis Treatment Shortening Trial |
| Official title | A Prospective Study of Shortening the Duration of Standard Short Course Chemotherapy From 6 Months to 4 Months in HIV-non-infected Patients With Fully Drug-Susceptible, Non-cavitary Pulmonary Tuberculosis With Negative Sputum Cultures After 2 Months of Anti-TB Treatment |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Tuberculosis |
| Intervention type | Drug |
| Interventions | Ethambutol, Isoniazid, Pyrazinamide, Rifampin |
| Enrollment | 394 |
| Start date | Apr 8, 2002 |
| Primary completion | Sep 2, 2008 |
| Completion | Nov 28, 2008 |
| First posted | Aug 15, 2005 |
| Last update posted | Nov 8, 2018 |
| Countries | Brazil, Philippines, Uganda |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: